West China Centre of Excellence for Pancreatitis, Institute of Integrated Traditional Chinese and Western Medicine, Sichuan Provincial Pancreatitis Centre and West China-Liverpool Biomedical Research Centre, West China Hospital, Sichuan University, Chengdu 610041, China.
Centre for Evidence-Based Chinese Medicine, Beijing University of Chinese Medicine, Beijing, 100010, China.
Phytomedicine. 2023 May;113:154727. doi: 10.1016/j.phymed.2023.154727. Epub 2023 Mar 2.
Evidence suggests that Dachengqi and its modified decoctions are effective for treating abdominal pain, multiple organ dysfunction syndrome (MODS) and inflammation in various disease conditions. We performed a meta-analysis to ascertain the effectiveness of a series of chengqi decoctions in patients with severe acute pancreatitis (SAP).
We searched Pubmed, Embase, Cochrane library, Web of Science, Chinese National Knowledge Infrastructure, Chinese Biomedical Literature, Wanfang database and China Science and Technology Journal Database before August 2022 to identify eligible randomized controlled trials (RCTs). Mortality and MODS were chosen as primary outcomes. Secondary outcomes included time until relief of abdominal pain, APACHE II score, complications, effectiveness, IL-6 and TNF-α levels. The risk ratio (RR) and standardized mean difference (SMD) with a 95% confidence interval (CI) were selected as effect measures. The quality of evidence was independently assessed by two reviewers using Grading of Recommendations Assessment Development and Evaluation (GRADE) system.
Twenty-three RCTs (n = 1865) were finally included. The results showed that, compared with routine therapies, chengqi-series decoctions (CQSDs) treatment groups were associated with lower mortality rate (RR: 0.41, 95%CI: 0.32 to 0.53, p = 0.992) and incidence of MODS (RR: 0.48, 95%CI: 0.36 to 0.63, p = 0.885). They also reduced remission time of abdominal pain (SMD: -1.66, 95%CI: -1.98 to -1.35, p = 0.000), complications (RR: 0.52, 95%CI: 0.39 to 0.68, p = 0.716), APACHE II score (SMD: -1.04, 95%CI:-1.55 to -0.54, p = 0.003), IL-6 (SMD: -1.5, 95%CI: -2.16 to -0.85, p = 0.000), TNF-α (SMD: -1.18, 95%CI: -1.71 to -0.65, p = 0.000), and improved curative effectiveness (RR:1.22, 95%CI: 1.14 to 1.31, p = 0.757). The certainty of the evidence for these outcomes was low to moderate.
CQSDs seem to be effective therapy for SAP patients with notable reductions in mortality, MODS and abdominal pain, with low quality evidence. Large-scale, multi-center RCTs that are more meticulous are advised in order to produce superior evidence.
有证据表明,大承气及其加减方在治疗各种疾病引起的腹痛、多器官功能障碍综合征(MODS)和炎症方面是有效的。我们进行了一项荟萃分析,以确定一系列承气汤在治疗重症急性胰腺炎(SAP)患者中的疗效。
我们检索了 Pubmed、Embase、Cochrane 图书馆、Web of Science、中国知网、中国生物医学文献、万方数据库和中国科技期刊数据库,以确定符合条件的随机对照试验(RCT)。死亡率和 MODS 被选为主要结局。次要结局包括腹痛缓解时间、APACHE II 评分、并发症、疗效、IL-6 和 TNF-α 水平。风险比(RR)和标准化均数差(SMD)及 95%置信区间(CI)被选为效应量。两名评审员使用推荐评估、制定与评价分级(GRADE)系统独立评估证据质量。
最终纳入 23 项 RCT(n=1865)。结果表明,与常规治疗相比,承气汤治疗组的死亡率(RR:0.41,95%CI:0.32 至 0.53,p=0.992)和 MODS 发生率(RR:0.48,95%CI:0.36 至 0.63,p=0.885)均较低。它们还缩短了腹痛缓解时间(SMD:-1.66,95%CI:-1.98 至 -1.35,p=0.000)、并发症(RR:0.52,95%CI:0.39 至 0.68,p=0.716)、APACHE II 评分(SMD:-1.04,95%CI:-1.55 至 -0.54,p=0.003)、IL-6(SMD:-1.5,95%CI:-2.16 至 -0.85,p=0.000)和 TNF-α(SMD:-1.18,95%CI:-1.71 至 -0.65,p=0.000),并提高了疗效(RR:1.22,95%CI:1.14 至 1.31,p=0.757)。这些结局的证据确定性为低到中等。
承气汤似乎是治疗 SAP 患者的有效疗法,可显著降低死亡率、MODS 和腹痛,但其证据质量较低。建议进行更大规模、多中心的 RCT,以产生更高质量的证据。